XML 21 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 28, 2018
Dec. 29, 2017
Current assets:    
Cash and cash equivalents $ 314,775 $ 183,164
Short-term investments 378,559 204,607
Short-term restricted cash and investments 0 504
Trade receivables, net 162,771 77,300
Other receivables 16,056 3,892
Inventory, net 9,838 6,657
Prepaid expenses and other current assets 15,017 8,750
Total current assets 897,016 484,874
Long-term investments 157,187 64,255
Long-term restricted cash and investments 1,100 4,646
Property and equipment, net 50,897 25,743
Operating lease right-of-use assets 5,867 0
Deferred tax assets, net 244,111 0
Goodwill 63,684 63,684
Other long-term assets 2,424 12,092
Total assets 1,422,286 655,294
Current liabilities:    
Accounts payable 10,901 9,575
Accrued compensation and benefits 32,142 21,073
Accrued clinical trial liabilities 18,231 19,849
Rebates and fees due to customers 14,954 7,565
Accrued collaboration liabilities 7,419 8,974
Current portion of deferred revenue 0 31,984
Other current liabilities 21,825 16,150
Total current liabilities 105,472 115,170
Long-term portion of deferred revenue 15,897 238,520
Long-term portion of lease liabilities 12,178 14,938
Other long-term liabilities 1,286 1,705
Total liabilities 134,833 370,333
Commitments
Stockholders’ equity:    
Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 296,209,426 and 289,923,798 at December 31, 2017 and 2016, respectively 300 296
Additional paid-in capital 2,168,217 2,114,184
Accumulated other comprehensive loss (701) (347)
Accumulated deficit (880,363) (1,829,172)
Total stockholders’ equity 1,287,453 284,961
Total liabilities and stockholders’ equity $ 1,422,286 $ 655,294